At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
Nivolumab +1 moredrug
Likely dose
Nivolumab 480mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Nivolumab + BMS-986016 (Relatlimab) in Patients With Metastatic Uveal Melanoma
In Brief
A Phase 2 clinical trial evaluating Nivolumab and Relatlimab for Metastatic Uveal Melanoma. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The purpose of this research is to test if a combination treatment of nivolumab and relatlimab will result in tumor reduction in patients with metastatic uveal melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Uveal Melanoma
CountriesUnited States
CollaboratorsBristol-Myers Squibb, United States Department of Defense
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartNov 2020
Primary CompletionJan 2024
Study CompletionJan 2026
TodayJul 2026
First PostedSep 17, 2020
Enrollment StartNov 10, 2020
Primary CompletionJan 4, 2024
Study CompletionJan 4, 2026
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 5.8 years ago
Interventions
Nivolumabdrug
Nivolumab 480mg administered intravenously on Day 1 of each 4 week cycle.
Relatlimabdrug
Relatlimab 160 mg administered intravenously on Day 1 of each 4 week cycle.